Chimeric SlpA Probiotic for CDI Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infection (CDI) are inadequate, as they often lead to disease relapse and antibiotic resistance, and existing vaccines have not been successful due to variability in surface-layer protein epitope antigenicity, necessitating a new approach for effective treatment and prevention.
Innovation Solution
A chimeric nucleic acid molecule and polypeptide comprising a phosphoglycerate mutase promoter and a bacterial surface layer protein A (SlpA) with a Clostridium difficile host-cell binding domain and a lactic acid bacterium-derived peptidoglycan anchor, engineered into a vector and administered to colonize the gut, thereby treating or preventing CDI.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibiotic treatments are used for CDI, then bacterial infection is suppressed, but disease relapse and antibiotic resistance occur
Solution Approach 1:
The invention uses the chimeric SLP protein, which is naturally produced by C. difficile as a virulence factor for host cell binding, and converts it into a beneficial therapeutic agent. By expressing this protein in probiotic bacteria, it competes with the pathogen for binding sites on host cells, blocking infection without using antibiotics, thus avoiding resistance development while utilizing the pathogen's own molecular mechanisms for protection
Solution Approach 2:
The invention introduces probiotic bacteria expressing chimeric SLP as an intermediary between the host and C. difficile. These engineered probiotics serve as mediators that occupy binding sites on host epithelial cells, preventing direct pathogen-host interaction. The chimeric protein acts as a molecular intermediary that mimics the pathogen's binding mechanism but without its harmful effects, thereby blocking infection in a non-antibiotic manner
2Reliability
If SLP-based vaccines are developed for CDI prevention, then immune response is targeted, but variability in epitope antigenicity reduces effectiveness
Solution Approach 1:
The invention applies local quality by creating a chimeric protein that combines the highly antigenic host-cell binding domain from C. difficile SLP with the stable peptidoglycan anchor domain from Lactobacillus. This localized optimization ensures that the immunogenic portion is derived from the pathogen (ensuring relevant immune recognition) while the anchor portion provides structural stability and consistent antigen presentation, thereby reducing variability in epitope antigenicity
Solution Approach 2:
The invention uses composite materials by constructing a chimeric SLP protein that fuses domains from two different bacterial sources: the N-terminal host-cell binding domain from C. difficile and the C-terminal peptidoglycan anchor domain from Lactobacillus. This composite structure combines the advantages of both parental proteins - the pathogen-specific antigenicity needed for effective immune recognition and the stable anchoring mechanism that ensures consistent expression and presentation, thereby overcoming the variability problem in pure C. difficile SLP vaccines
3Reliability
If probiotic bacteria are engineered to express chimeric SLP, then gut colonization and pathogen competition are achieved, but genetic modification complexity increases
Solution Approach 1:
The invention applies segmentation by dividing the chimeric SLP gene construct into distinct functional modules: the host-cell binding domain from C. difficile, the peptidoglycan anchor domain from Lactobacillus, and appropriate linkers or fusion regions. This modular design facilitates targeted genetic engineering, allows independent optimization of each domain, and simplifies the cloning and expression process in probiotic bacteria, thereby reducing overall genetic engineering complexity while maintaining gut colonization capability
Data Source
AI summary
The invention features engineered probiotic lacto acid bacteria (LAB) expressing a chimeric Clostridium difficile/Lactobacillus acidophilus SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.